Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
The manufacturer must clearly state in the product manual that "for research use only, not for human treatment", and remind users to be aware of potential risks
Beer is a board-certified practitioner with a private practice, but is also a clinical instructor in the NYU Nurse Practitioner program and a lecturer at the Mount Sinai Medical Center
How to Use Enhanced Yohimbine
Peptides are sold in powder form and need Reconstitution Solution to mix with them
You'll work with our lab on creating your very own